Identification of CD105+ Extracellular Vesicles as a Candidate Biomarker for Metastatic Breast Cancer.

Biomarkers Biomarkers, Tumor Breast Neoplasms / diagnosis Extracellular Vesicles / pathology Female Humans Pilot Projects Receptors, Progesterone
Biomarkers Breast cancer CD105 Endoglin Exosomes Extracellular vesicles

Journal

The Journal of surgical research
ISSN: 1095-8673
Titre abrégé: J Surg Res
Pays: United States
ID NLM: 0376340

Informations de publication

Date de publication:
12 2021
Historique:
received: 31 01 2021
revised: 17 05 2021
accepted: 14 06 2021
pubmed: 28 7 2021
medline: 7 4 2022
entrez: 27 7 2021
Statut: ppublish

Résumé

Extracellular vehicles (EVs) released by malignant tumor cells can mediate the immune response and promote metastasis through intercellular communication. EV analysis is an emerging cancer surveillance tool with advantages over traditional liquid biopsy methods. The aim of this pilot study is to identify actionable EV signatures in metastatic breast cancer. Under an IRB-approved protocol for the analysis of patient plasma, samples were collected from women with newly diagnosed or progressive metastatic breast cancer and from women without cancer. Enriched EVs were analyzed via a bead-based multiplex assay designed to detect 37 distinct tumor-relevant epitopes. The mean fluorescent intensity of EV epitopes meeting a minimum threshold of detectability was compared between groups via independent samples t-test. Subgroup analysis was conducted for metastatic breast cancer patients who were positive for estrogen and/or progesterone receptors and negative for HER2. Other variables potentially affecting CD105 levels were also analyzed. CD105 was found to have a significantly higher mean fluorescent intensity in participants with metastatic breast cancer compared to control participants (P = 0.04). ER/PR+ subgroup analysis revealed a similar pattern compared to control participants (P = 0.01). Other analyzed variables were not found to have a significant correlation with CD105 levels. CD105 EV levels were significantly higher in samples from participants with breast cancer compared to controls. Given that CD105 is known to mediate angiogenesis and promote metastasis, EV-associated CD105 in plasma represents a potential biomarker for diagnosis, surveillance and therapeutic targeting in patients with metastatic breast cancer.

Sections du résumé

BACKGROUND
Extracellular vehicles (EVs) released by malignant tumor cells can mediate the immune response and promote metastasis through intercellular communication. EV analysis is an emerging cancer surveillance tool with advantages over traditional liquid biopsy methods. The aim of this pilot study is to identify actionable EV signatures in metastatic breast cancer.
MATERIALS AND METHODS
Under an IRB-approved protocol for the analysis of patient plasma, samples were collected from women with newly diagnosed or progressive metastatic breast cancer and from women without cancer. Enriched EVs were analyzed via a bead-based multiplex assay designed to detect 37 distinct tumor-relevant epitopes. The mean fluorescent intensity of EV epitopes meeting a minimum threshold of detectability was compared between groups via independent samples t-test. Subgroup analysis was conducted for metastatic breast cancer patients who were positive for estrogen and/or progesterone receptors and negative for HER2. Other variables potentially affecting CD105 levels were also analyzed.
RESULTS
CD105 was found to have a significantly higher mean fluorescent intensity in participants with metastatic breast cancer compared to control participants (P = 0.04). ER/PR+ subgroup analysis revealed a similar pattern compared to control participants (P = 0.01). Other analyzed variables were not found to have a significant correlation with CD105 levels.
CONCLUSIONS
CD105 EV levels were significantly higher in samples from participants with breast cancer compared to controls. Given that CD105 is known to mediate angiogenesis and promote metastasis, EV-associated CD105 in plasma represents a potential biomarker for diagnosis, surveillance and therapeutic targeting in patients with metastatic breast cancer.

Identifiants

DOI: 10.1016/j.jss.2021.06.050 PMID: 34314883 PMC: PMC8805608
pubmed: 34314883
pii: S0022-4804(21)00430-3
doi: 10.1016/j.jss.2021.06.050
pmc: PMC8805608
mid: NIHMS1773551
pii:
doi:

Substances chimiques

Biomarkers 0
Biomarkers, Tumor 0
Receptors, Progesterone 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

168-173

Subventions

Organisme : NCI NIH HHS
ID : R01 CA236386
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA121938
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM140137
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA023100
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA174869
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Références

Rom J Morphol Embryol. 2013;54(3 Suppl):701-7
pubmed: 24322015
Tumour Biol. 2015 Feb;36(2):737-45
pubmed: 25286761
Biomolecules. 2020 Feb 12;10(2):
pubmed: 32059544
FASEB J. 2018 Jun;32(6):2934-2949
pubmed: 29401587
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638
pubmed: 29795272
Genes Cancer. 2018 Mar;9(3-4):87-100
pubmed: 30108680
J Extracell Vesicles. 2019 May 28;8(1):1615820
pubmed: 31191831
AAPS J. 2017 Nov 27;20(1):1
pubmed: 29181730
Cancer Res. 2011 Aug 1;71(15):5346-56
pubmed: 21670082
Clin Cancer Res. 2019 Jan 1;25(1):266-276
pubmed: 30287549
Stem Cells Int. 2019 Mar 19;2019:9060152
pubmed: 31015843
Cell. 2015 May 21;161(5):1046-1057
pubmed: 26000481
J Control Release. 2021 Mar 10;331:404-415
pubmed: 33485883
World J Surg Oncol. 2020 May 20;18(1):99
pubmed: 32434528
Pediatr Nephrol. 2019 Jan;34(1):11-30
pubmed: 29181712
FASEB J. 2003 Jun;17(9):984-92
pubmed: 12773481
Clin Cancer Res. 2008 Apr 1;14(7):1931-7
pubmed: 18381930
Int J Cancer. 2000 Mar 20;89(2):122-6
pubmed: 10754488
Cell Commun Signal. 2020 Oct 20;18(1):163
pubmed: 33081785
Cancer Immunol Immunother. 2013 Mar;62(3):541-51
pubmed: 23076642
J Control Release. 2015 Dec 10;219:396-405
pubmed: 26241750
J Exp Clin Cancer Res. 2018 Mar 2;37(1):42
pubmed: 29499713
Mol Pharm. 2018 Jul 2;15(7):2606-2613
pubmed: 29787283
J Surg Oncol. 2006 Oct 1;94(5):413-7
pubmed: 16967447
Cancer Lett. 2018 Oct 28;435:80-91
pubmed: 30098399
Mol Ther Nucleic Acids. 2018 Mar 2;10:131-141
pubmed: 29499928

Auteurs

Sasha R Douglas (SR)

Department of Surgery, University of California San Diego, La Jolla, California.

Kay T Yeung (KT)

Department of Medicine, Division of Hematology and Oncology, University of California San Diego, La Jolla, California.

Jing Yang (J)

Department of Pharmacology, Moores Cancer Center, University of California San Diego, California.

Sarah L Blair (SL)

Division of Breast Surgery and The Comprehensive Breast Health Center, University of California San Diego, La Jolla, California.

Olga Cohen (O)

Department of Surgery, University of California San Diego, La Jolla, California.

Brian P Eliceiri (BP)

Department of Surgery, University of California San Diego, La Jolla, California. Electronic address: beliceiri@health.ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Identification of CD105+ Extracellular...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Identification of CD105+ Extracellular...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Identification of CD105+ Extracellular...
questionsmedicales.fr › Cellules › Structures cellulaires › Espace extracellulaire › Vésicules extracellulaires › Identification of CD105+ Extracellular...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Identification of CD105+ Extracellular...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Projets pilotes › Identification of CD105+ Extracellular...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs à la progestérone › Identification of CD105+ Extracellular...